The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with massive upside for 2026.

As CASGEVY reinforced confidence in the company’s long-term growth outlook, CRISPR Therapeutics AG (NASDAQ:CRSP) received fresh support from Wall Street.

On May 13, 2026, Bernstein raised its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $56 from $50 while keeping a “Market Perform” rating. The firm pointed to a strong start for biotech in 2026, with the sector up 11% year-to-date and outperforming both pharma and the S&P 500. Bernstein maintained a positive view on the space, citing expectations for healthy M&A and IPO activity and characterizing recent FDA leadership changes as a tailwind, particularly for less mature companies.

That update followed Q1 2026 results reported on May 4, 2026.

CASGEVY, the company’s approved gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia (TDT), generated $43 million in revenue during the quarter, with more than 500 patients having initiated treatment worldwide. Net loss narrowed to $122.9 million, or $1.28 per share, from $136.0 million a year earlier. R&D expenses came in at $68.6 million and G&A at $17.2 million, both lower than the prior-year period.

Cash, cash equivalents, and marketable securities strengthened to $2.44 billion as of March 31, 2026, up from $1.98 billion at year-end 2025, driven largely by $585.4 million in net proceeds from convertible senior notes issued in March. CEO Samarth Kulkarni said 2026 “will be a defining year” for CRISPR Therapeutics AG (NASDAQ:CRSP), citing pipeline milestones ahead.

Meanwhile, on May 5, 2026, BofA trimmed its price target to $83 from $86 but kept a “Buy” rating, saying the Q1 updates left its core thesis largely unchanged.

Overall, 14 out of 26 covering analysts hold bullish views on CRISPR Therapeutics AG (NASDAQ:CRSP).

CRISPR Therapeutics AG (NASDAQ:CRSP) develops gene-editing therapies for serious diseases using its CRISPR/Cas9 platform technology.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.